New hepatitis C therapies for special patient populations (Q40899794)

24 September 2017

New hepatitis C therapies for special patient populations (English)

1 reference

24 September 2017

1

Vincent Soriano

1 reference

24 September 2017

Pablo Labarga

2

1 reference

24 September 2017

Carmen de Mendoza

3

1 reference

24 September 2017

José V Fernández-Montero

4

1 reference

24 September 2017

Isabella Esposito

5

1 reference

24 September 2017

Laura Benítez-Gutiérrez

6

1 reference

24 September 2017

José M Peña

7

1 reference

24 September 2017

Pablo Barreiro

8

1 reference

24 September 2017

language of work or name

English

0 references

publication date

23 November 2015

1 reference

Expert Opinion on Pharmacotherapy

24 September 2017

1 reference

24 September 2017

17

1 reference

24 September 2017

217-229

1 reference

24 September 2017

2

1 reference

Global control of hepatitis C: where challenge meets opportunity

24 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Global epidemiology and genotype distribution of the hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Outcome of posttransplantation hepatitis C virus disease--is it the host, the virus, or how we modify the host and/or the virus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Pharmacokinetics of new oral hepatitis C antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

New hepatitis C therapies: the toolbox, strategies, and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Continued progress against hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Drug interactions with new hepatitis C oral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Drug-drug interactions during antiviral therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Update on hepatitis C virus resistance to direct-acting antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Towards hepatitis C eradication from the HIV-infected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Simeprevir for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis C therapy with HCV NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

An interferon-free antiviral regimen for HCV after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Daclatasvir + asunaprevir: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

HCV targeting of patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis B virus and hepatitis C virus dual infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Management of hepatitis C in HIV and/or HBV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Clinical and virological profiles in patients with multiple hepatitis virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Emerging challenges in managing hepatitis B in HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Viral hepatitis: Treating hepatitis C in injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis C treatment for injection drug users: a review of the available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Threading the Needle--How to Stop the HIV Outbreak in Rural Indiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

HIV and viral hepatitis coinfections: advances and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Treatment failure with new hepatitis C drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Management of direct-acting antiviral agent failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Extrahepatic manifestations of hepatitis C infection: navigating CHASM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis C cure with antiviral therapy--benefits beyond the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Extrahepatic morbidity and mortality of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Chronic hepatitis C in childhood: an 18-year experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

New treatments for chronic hepatitis C: an overview for paediatricians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Prevalence and management of chronic hepatitis C virus infection in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Hypoglycemia in a diabetic patient during hepatitis C therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

EASL Recommendations on Treatment of Hepatitis C 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1112790

10.1517/14656566.2016.1112790

21 January 2018

Identifiers

DOI

1 reference

release_k2uk7h2t6fejnbtstvzcbp5p34

24 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/k2uk7h2t6fejnbtstvzcbp5p34

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference